AUTHOR=Tan Yujing , Wang Yu , Liu Xiaoyan , Ma Qin , Zeng Cheng , Zhu Aihua , Sun Xiaoying , Ma Fei , Wang Jiani 

TITLE=Case Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancer

JOURNAL=Frontiers in Immunology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1589191

DOI=10.3389/fimmu.2025.1589191

ISSN=1664-3224

ABSTRACT=Drug-induced sarcoidosis-like reaction (DISR) is a rare adverse event associated with immunotherapy. Currently, there is no standardized treatment protocol for DISR linked to immune checkpoint inhibitors (ICIs). This study presents a case of an early-stage triple-negative breast cancer (TNBC) patient who developed hepatic sarcoidosis-like reactions during neoadjuvant pembrolizumab therapy. We provide an overview of ICI-induced sarcoidosis-like reactions in cancer patients, including incidence, mechanisms, clinical manifestations, treatment, and prognosis. Additionally, we discuss the significance of one-year adjuvant immunotherapy for early-stage TNBC patients who achieved pathological complete response after neoadjuvant therapy, offering insights for individualized therapeutic strategies in this population.